Currently, five EGFR-TKIs are available as the first-line (1L) therapy for advanced EGFR mutation-positive NSCLC—first-generation (1G) reversible EGFR-TKIs, gefitinib, and erlotinib; second-generation (2G) irreversible ErbB family blockers, afatinib, and dacomitinib; third-generation (3G) irreversible EGFR-TKIs, osimertinib. Here, EGFR is linked to non-small cell lung carcinoma.